...
首页> 外文期刊>Marine Drugs >The Marine Fungal Metabolite, AD0157, Inhibits Angiogenesis by Targeting the Akt Signaling Pathway
【24h】

The Marine Fungal Metabolite, AD0157, Inhibits Angiogenesis by Targeting the Akt Signaling Pathway

机译:海洋真菌代谢物AD0157通过靶向Akt信号通路抑制血管生成

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In the course of a screening program for the inhibitors of angiogenesis from marine sources, AD0157, a pyrrolidinedione fungal metabolite, was selected for its angiosupressive properties. AD0157 inhibited the growth of endothelial and tumor cells in culture in the micromolar range. Our results show that subtoxic doses of this compound inhibit certain functions of endothelial cells, namely, differentiation, migration and proteolytic capability. Inhibition of the mentioned essential steps of in vitro angiogenesis is in agreement with the observed antiangiogenic activity, substantiated by using two in vivo angiogenesis models, the chorioallantoic membrane and the zebrafish embryo neovascularization assays, and by the ex vivo mouse aortic ring assay. Our data indicate that AD0157 induces apoptosis in endothelial cells through chromatin condensation, DNA fragmentation, increases in the subG1 peak and caspase activation. The data shown here altogether indicate for the first time that AD0157 displays antiangiogenic effects, both in vitro and in vivo, that are exerted partly by targeting the Akt signaling pathway in activated endothelial cells. The fact that these effects are carried out at lower concentrations than those required for other inhibitors of angiogenesis makes AD0157 a new promising drug candidate for further evaluation in the treatment of cancer and other angiogenesis-related pathologies.
机译:在从海洋来源筛选血管生成抑制剂的过程中,选择了吡咯烷二酮类真菌代谢物AD0157,因为它具有血管抑制作用。 AD0157在微摩尔范围内抑制培养物中内皮细胞和肿瘤细胞的生长。我们的结果表明,该化合物的亚毒性剂量会抑制内皮细胞的某些功能,即分化,迁移和蛋白水解能力。抑制上述体外血管生成的基本步骤与观察到的抗血管生成活性相一致,通过使用两种体内血管生成模型,绒膜尿囊膜和斑马鱼胚胎新血管形成测定法以及离体小鼠主动脉环测定法得以证实。我们的数据表明,AD0157通过染色质浓缩,DNA片段化,subG1峰增加和胱天蛋白酶激活来诱导内皮细胞凋亡。此处显示的数据首次表明,AD0157在体外和体内均显示出抗血管生成作用,这部分是通过靶向活化的内皮细胞中的Akt信号通路来发挥的。这些作用是在比其他血管生成抑制剂所需的浓度更低的浓度下进行的事实,使AD0157成为新的有希望的候选药物,可用于进一步评估癌症和其他与血管生成相关的病理学治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号